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Abstract 
Conventional allogeneic bone marrow transplantation after 
myeloablation can prevent experimental autoimmunity and 
bas been proposed as treatment for humans. However, trace 
populations of donor hematolymphoid cells persisting in 
solid organ allograft recipients have been associated in some 
circumstances with therapeutic effects similar to replace-
ment of the entire bone marrow. We therefore examined 
whether inducing hematolymphoid microchimerism with-
out myeloablation could confer the ability to resist mercuric 
chloride (HgCI2)-induced autoimmunity. 
Brown-Norway (BN) rats were pretreated with a synge-
neic or allogeneic bone marrow infusion under transient 
FK506 immunosuppression before receiving HgCh. they 
were compared with BN rats receiving either no pretreat-
ment (naive) or FKS06 alone. Administration of HgCI2 to 
naive BN rats induced marked autoantibody production, 
systemic vasculitis and lymphocytic infiltration of the kid-
neys, liver and skin in all of the animals and a 47% mortal-
ity. In contrast, BN rats pretreated with HgCh-resistant al-
logeneic Lewis bone marrow and transient FK506 showed 
less clinical disease and were completely protected from 
mortality. More specifically, IgG anti-Iaminin autoantibody 
production was decreased by 40% (P < 0.05), and there was 
less histopathological tissue injury (P < 0.(05), less in vitro 
autoreactivity (P < 0.05), less of an increase in class II 
MHC expression on B cells (P < 0.01), and 22% less weight 
loss (P < 0.01). compared with controls. Protection from the 
experimental autoimmunity was associated with signs of 
low grade activation of the BN immune system, which in-
cluded: increased numbers of circulating B and activated T 
cells before administration of HgCh. and less autoreactivity 
and spontaneous proliferation in vitro after HgC12. (J. Clin. 
Invest. 1996. 97:217-225.) Key words: bone marrow trans-
plantation • microchimerism • immunosuppPSssion • mer-
curic chloride. vasculitis 
Introduction 
Autoimmune diseases affect ~ 2.5% of the general population 
(1-3) and account for 20-25% of the patients on waiting lists 
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for liver and kidney transplantation (4. 5). Although T lym-
phocytes play an important role in these disorders, the exact 
pathogenesis remains unknown. 
Two primary theories have been proposed to explain the 
generation of pathogenic autoreactivity. While both concede 
the immune system to be the disease mediator, the first theory 
attributes autoimmunity to a failure of central tolerance. This 
reasoning would support the use of immunosuppressive ther-
apy as treatment (6, 7). The other hypothesis implicates im-
mune network abnormalities and dysfunctional peripheral 
control mechanisms as important contributing factors. This 
viewpoint would support stimulation of ill-defined "peripheral 
immune regulatory networks" as a therapeutic approach (8. 9). 
Conventional allogeneic bone marrow transplantation af-
ter recipient pre-conditioning with lethal irradiation. has al-
ready been used to correct immune system abnormalities and 
cure autoimmune disorders in experimental animals and advo-
cated as therapy in humans (10, 11). Although the concept of 
endowing the recipient with a normal (donor) immune system. 
is beguilingly simple. evidence has accrued which suggests that 
such a draconian step is not required. A surprising therapeutic 
effect can be achieved in some instances with the presence of 
only a trace population of persistent donor leukocytes (micro-
chimerism). such as that recently observed in successfully 
treated animal and human whole organ allograft recipients un-
der conventional immunosuppression (12-15). Examples of 
the profound immunological sequelae of microchimerism in-
clude avoidance of graft-versus-host reactions (13-17); toler-
ance to whole vascularized organ allografts from the original 
donor (12-15,18,19); transfer of delayed-type hypersensitivity 
responses (20) and switching of ABO blood group types (21). 
Indeed. we have postulated that successful whole organ 
transplantation allows a small component of the donor im-
mune system to disseminate from the allograft. and eventually 
integrate with. and change. the overall properties of the much 
larger recipient immune system (22. 23)-similar to the "toler-
ance by network stimulation" hypothesis of Coutinho (24. 25). 
The immunologic consequences of whole organ transplanta-
tion are thus the same as if bone marrow alone was infused. as 
we have previously shown in experiments using Lewis (LEWY 
to Brown-Norway (BN) rat transplantation models (15,23). In 
BN rats. injection of HgCl, induces the emergence of autore-
active anti-Ia T lymphocytes that stimulate the production of 
several well-defined autoantibodies by B cells (26). This re-
sults in a widespread vasculitis. with lymphocytic infiltration 
and damage to the skin and visceral organs. and upregulation 
of class II MHC antigens on affected tissues (26. 27), In ani-
mals that survive the acute syndrome. the autoreactive cells di-
I. AbbreviaTIons used in rhis paper: AI. autoimmune: BN. Brown· 
Norway rat; LEW. Lewis rat: HgCl,. mercuric chloride; MLR. mixed 
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minish and regulatory T cells appear. which render the rats 
resistant to additional egC~ injections (28). These regulatory 
T cells can then be used to transfer resistance to naive BN 
rats (28). 
In the present experiments we have tested the hypothesis 
that the induction of microchimerism (LEW ~ BN) with a 
bone marrow infusion might confer the normal resistance to 
mercuric chloride Eeg~F autoimmunity of the LEW rat on 
the normally AI-sensitive BN recipient. 
Methods 
Animals. Adult 7-8-wk-old inbred male rats weighing 200-250 grams 
were purchased from Harlan Sprague Dawley Inc. (Indianapolis. IN) 
and maintained in specific pathogen-free animal facilities with access 
to rat chow and water ad libitum Lewis rats (LEW; RTlI) were used 
as bone marrow allograft donors. Brown-Norway (BN; RTl n) rats 
were used as recipients and as the susceptible strain for HgCI2-
induced Al disease. 
Induction and monitoring of autoimmune disease. and transplan-
tation procedures. Autoimmune disease was reproducibly induced in 
naive QN rats (group II. n = 15) with five subcutaneous injections of 
100 ",gll00 grams bodyweight of HgCI2 (Sigma Chemical Co .• St. 
Louis. MO) given over 9 d. from day 0 to day 8. as a 0.1 % solution in 
distilled water. In this model. autoantibody production routinely 
peaks at 12-14 d. whereas the worst clinical disease occurs around 21 
d (29). BN rats (group I. n = 5) receiving equivalent injections of car-
rier only. served as negative controls. 
As previously described (23). hematolymphoid microchimerism 
was produced 100 d before subsequent HgCl2 therapy by infusing 
2.5 x 10" unfractionated bone marrow cells ("-' I donor/recipient) 
into the penile vein of BN recipients. The bone marrow was har-
vested from the femurs. tibias and humeri uf LEW donor rats using 
RPM I 1640 supplemented with 25 mM Hepes buffer. 2 mM l-gluta-
mine. 50 U/ml penicillin. and 50 f.Lg/ml streptomycin (ail obtained 
from GIBCO. Life Technologies Inc .. Grand Island. NY). The BN re-
cipients were then treated with daily intramuscular FK506 injections 
(dissolved in HCO-60 and 0 mannitol; Fujisawa Pharmaceutical Co. 
Ltd .. Osaka. Japan) of 1 mglkg per day for 14 d and with two extra in-
jections of the same dose on day -80 and day -72. at which stage all 
immunosuppression was stopped. On day 0 the same HgCI2 protocol 
as above was commenced. Alone. this transient FK506 treatment pro-
tocol has been shown to have no effect on organ allograft survival by 
day 0 (23). 
BN rats (n = 13) rendered microchimeric in this fashion (group 
V) were compared with two control groups: BN rats (n = 6) that re-
ceived only the FK506 treatment protocol outlined above (group III), 
and BN rats (n = 11) that received an identical amount of syngeneic 
BN bone marrow plus the same FK506 regimen (group IV) (see Ta-
ble I). 
All animals were examined daily for clinical signs of AI disease 
(hair loss. erythema affecting the paws. chest. and peri-oral area). and 
weighed every second day. "Minor" changes were defined as detect-
able perioral and pedal erythema: "moderate" changes were obvious 
perioral. labial and pedal erythema with trace ulceration: "severe" 
changes were defined as extensive erythema of the chest wall. perio-
ral. labial, and footpads with swelling. ulceration. and crusting of the 
lesions. 
Enzyme linked immunosorbent aSSD.\ls. ELISAs were performed 
using a modification of a previously described technique (30). Poly-
styrene microtiter plates (Nunc. Kamstrap. Denmark) were coated 
with 10 ~glmllaminin (Sigma Chemical Co .. S1. Louis. MO) in 10 mM 
Tris-HCl buffer (pH 7.4). After washing with PBS containing 0.05% 
Tween 20. the laminin-coated plates were blocked with protein block-
ing agent (Lipshaw Immunon. Pittsburgh. PAl. washed. and incu-
bated for 60 min with 100 ~l test serum diluted to 1:100. Wells were 
then washed and incubated with either alkaline phosphatase-canju· 
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gated goat anti-rat IgG or goat anti-rat IgM (both diluted 
Jackson Immunoresearch Inc .. West Grove. PAl. Alkaline 
phatase activity was localized with p-flitro-l)he'nyl-phO!lphlatcl·. 
strate and buffer (Moss Incorporated. Pasadena. MD) and the 
uct was quantitated by measuring extinction at 405 nm using a 
kinetic microplate reader (Molecular Devices. Menlo Park. 
Sera were assayed in quadruplicate and results (optical 
1(00) are expressed as mean:!:SD for each time point. 
White cell counts and flow cYlometric analysis. Blood 
were taken from the tail artery and lymphocyte counts were 
with a hemocytometer after suspension of heparinized blood 
dilution in 2.86% glacial acetic acid. Double irnmunO!stai:niJIll: 
flow c:ytometric analysis was used to determine lymphocyte 
profiles. After RBC lysis (Red Cell Lysing Buffer (PH 7.5]; 
Chemical Co.), 2.5 x 10' cells were incubated for 20 min at 
wells containing biotinylated OX-19 (CD5. peripheral T 
OX-6 (MHC class II common determinant) in combination 
crrC-conjugate~lu-19I W3125 (CD4; T helper subset. 
phages) or OX-8 (CDS; MHC class I restricted T cells, NK 
measure B ceils, lymphOCytes were single stained with unl:l~fgultati 
OX-33 (CD45RA; B-cell common leukocyte antigen). All 
antibodies were of mouse IgGI isotype and were obtained 
tee (Oxford. England). After washing with ice cold PBS COtlwailm 
1 % BSA and 0.1 % sodium azide (both from Sigma Chemical 
ther streptavidin-phycoerythrin (Accurate Chemical Corp .• 
bury. NY) or FITC-conjugated goat anti-mouse antibody (for 
33; Serotec) were added for a further 20 min before washing. 
were fixed with 1 % paraformaldehyde and analyzed on an EPICS 
Elite flow cytometer (Coulter Corporation. Hialeah. FL) with acqui-
sition of ten thousand lymphocyte·gated events for each sample. 
FITC-conjugated mouse IgG I isotype and goat anti-mouse me 
were used as controls. and unstained cells were incorporated to asseSs 
autofluorescence. 
Histology and immunohislochemistry. Recognizing that animals 
with the most severe pathology died early of their disease. those ani-
mals that survived for 30 d from each group were killed for histo-
pathological analysis. Tissue samples from the kidney. skin. liver, and 
lung were fixed in 10% neutral-buffered formalin. paraffin-embed-
ded and routinely stained with haematoxylin and eosin. Additional 
tissue fragments from the same organs were snap-frozen in optimal 
cold temperature compound (O.C.T.; Miles Inc .. Elkhart. IN) for im-
munofluorescent studies that were carried out 011 4-f.Lm cryostat sec-
tions fixed in cold acetone at - 20"C and stained with FITC·conju-
gated goat anti-rat IgG or IgM (Cappel. Organon Teknika Corp .. 
West Chester. PAl at dilutions of 1:100 and 1:50. respectively. Nor-
mal BN kidnc;ys and spleen tissues were used as negative and positive 
controls. respectively. The routine light microscopy and immunofluo-
rescence studies were blindly evaluated by two observers (C. P. 
Delaney and A. J. Demetris). 
The severity of the tissue pathology associated with HgCll in-
duced autoimmunity was semi-quantitatively evaluated. based on a 
combination of the severity of inflammation and tissue injury in eacll 
organ. Lung pathology was excluded because of spontaneous compli-
cating changes observed in the BN strain. No inflammation or tissue 
injury was given a score of O. The combination of moderate. predomi-
nantly mononuclear inflammation associated with tissue injury in > 
one-half of the area of affected organs was given a score of three. 1be 
total score for an individual rat was obtained by adding the score 
from each organ. 
Mixed leukocyte reactions (MLR) and proliferative assays. Lym-
phocytes were obtained from the cervical lymph nodes of subject ani-
mals. Stimulator cells were harvested from normal BN animals and ir-
radiated with 2000 rads. Varying numbers of responder cells were 
mixed with a constant number of stimulators (lCf) in 96-well V-bot-
tomed plates (Falcon. Oxnard. CA) to give final responder:stimulator 
ratios of 4:1 in a final volume of 200 f.L1 of complete medium (RPM! 
1640 with added 10% normal BN serum. ; ILglml of gentamicin. 5.5 X 
10-' M 2-ME. 2 mM l·glutamine. 10 mM Hepes buffer and 0.5 f.Lg/mi 
Table J. Clinical Features, Weight Loss. and Mortality of Normal and Pretreated BN Rats Given HgC/2 
Clinical manifestations after egC~D Deaths at day 30 
Weight 
Group Pretreatment n None Minor Moderate Severe loss' Number Percent 
% 
Neg. control 
(saline) 5 5 0 0 
II Pos. control 15 2 6 7 22 7 47 
III FK506 6 2 3 21 2 33 
IV BN (syngeneic) 
bone marrow 
plusFK506 11 2 5 2 2 20 l' 9 
V LEW (allogeneic) 
bone marrow 
plus FK506 13 11' 2 Hill 0' 0 
Although pretreatment with FK506 with or without syngeneic bone marrow (groups III and IV) conferred some protection from egC~ autoimmu-
nity. animals treated with allogeneic bone marrow infusion plus transient FlCS06 at day -100 (group V) had the most effective protection from the 
clinical features and mortality associated with the disease. All significant differences are indicated and statistical analyses used are indicated in foot-
notes. *Erythema affecting paws. chest and peri-oral area (see Fig.!. Methods). 'Maximum mean weight change. as a percentage of initial body-
weight. I P < 0.005 vs. group II. and IV, Chi-squared test. 'p < 0.01 vs. group II. Chi-squared test. ip < 0.005 vs. groups II. III. and IV. Student's I test. 
of NMA). Cultures were incubated at 37°C for 96 h in 5% CO2 in hu-
midified air. Each well was pulsed with 0.2 I-LCilml final concentration 
of tritiated thymidine (2 CilmM; New England Nuclear. Beverly. 
MA) for the final 7 h of incubation. before automatic harvesting 
(Skatron. Lier. Norway) and analysis in a liquid scintillation counter 
(Wallac. Gaithersburg. MD). 
For baseline proliferation assays. 10-' cells from subject animals at 
day 0 in each group being tested were placed in quadruplicate in 96-
well plates using complete medium. cultured for 24 h. labeled and 
harvested as for the MLR plates. Proliferation assays and MLR were 
also repeated at day 30. using cervical lymph node·derived lympho-
cytes fTClm animals surviving HgCl2 disease. Results presented 
throughout the manuscript are from a minimum of three experi-
ments. 
Slatistical analysis. Results are expressed as mean:!: SD or 
mean:!:SEM. Student's I test and the Chi-squared test were used as 
indicated in the text. and a P value of < 0.05 was considered to be sig-
nificant. 
Results 
Protection from autoimmune disease. Naive BN animals given 
no treatment other than HgCl2 (group II) developed a severe 
AI syndrome associated with significant weight loss and a 47% 
mortality by day 30 (Table I). The obvious clinical manifesta-
tions included peri-oral. labial. anterior chest wall and pedal 
erythema (Fig. 1 A). with associated hair loss and ulceration in 
the same distribution. 
Histopathological examination of the skin showed a Iym-
phoplasmacytic infiltrate in the upper dermis. which extended 
into basal epidermal and hair shaft epithelium, where it was 
associated with prominent epithelial cell apoptosis (Fig. 2). 
Analysis of the kidneys revealed mild mesangial hypercellular-
ity. with a mild to moderate lymphoplasmacytic and eosino-
philic interstitial inflammatory infiltrate. associated with tubu-
Figure 1. Demonstration of the amount of protectIon from the clinical manifestations of egCl~-induced AI disease that can be achieved with dif-
ferent pretreatment protocols. Normal BN animals given egCl~ develop severe clinical changes (peri-oral. chest wall. and foot-pad erythema 
and ulceration) after 21 d (group II: A). Pretreatment with syngenetc bone marrow and transIent FK506 (group IV) affords partial protection 
from these changes (B). as does FK506 alone (group III). However. an allogeneic bone marrow infusion with transient FK506 (group VI abro-
gates these clinical features and the animals appear normal at all times (C). stgnificantly better than the protectton seen in groups III and IV. 
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lar epithelial infiltration and damage (Fig. 3). This resulted in 
tubular dilatation at the corticomedullary junction. Inflamma-
tion of a similar composition was present in the portal tracts of 
the liver. where infiltration and bile duct injury were evident 
(Table II). 
All of the treatment protocols used resulted in at least 
some protection from the clinical manifestations and mortality 
;... 
Figure 2. Light microscopic evaluation of hematoxylin and eosin 
stained sections from the skin of negative control animals (A; group'. 
I). positive controls (B: group II) and animals pretreated with alJogei . 
neic bone marrow and transient FKS06 (C; group V). 30 d after in-
duction Al disease with HgCl2. Note the moderate lymphocytic in- . 
flammatory infiltrate of the upper dermis which extends into the hair 
shafts and epidermis and is associated with epithelial cell apoptosis 
(inset). These changes were partially prevented in groups III and IV. 
but completely prevented in group V animals (see Table II). 
seen after HgCl2 injections. with significant protection seen in 
Groups IV and V (Table I. Fig. 1), However. the most compre-
hensive protection was observed in BN animals pretreated at 
day -100 with an allogeneic bone marrow infusion in combi-
nation with the transient course of FK506 immunosuppression 
(group V) (Table I). The complete absence of mortality, the 
significantly reduced weight loss. the presence of minimal der-
Table I/. Histopathological Evaluation of Inflammation and Damage Occurring.in Animals That Survived for 30 d after Starting 
HgCI] Injections 
Immunofluorescence 
Mean score per tissue l (lgM) 
Group Treatment n HgCI, Skin Kidney Liver Total· Kidney' 
Naive 3 0.0 0.0 0.2 0.2 0 
II Naive 5 + 1.6 1.6 1.4 4.6 S 
III FKS06 alone 5 + 0.2!1** I.S11 0.8 2.Slltt 2.S 
IV BN (syngeneic) 
bone marrow 
plus FKS06 10 + 0.81! 1.2** 1.0 3.(1I1l 3.5 
V LEW (allogeneic) 
bone marrow 
plus FKS06 II + 0.0' 0.8' 0.6' 1.4' 1.5 
Rats dying before 30 d were not included in this analysis. Significant differences are indicated (Student's I test). ·Total score fOT each group by adding 
scores for separate tissues. I Mean score for each tissue after blinded histological evaluation of sections. I Representative score on a scale of O-S. after 
blind grading of kidney sections stamed with goat anti-rat IgM.:P < 0.05 vs. group II. ' P < 0.005 vs. group II. •• P < 0.05 vs. group V." P < 0.005 vs. 
group V. 
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mal changes (in only two animals). and the less severe histo-
pathologic evidence of tissue injury documented the clinical 
and pathological amelioration seen in these animals (Table I. 
Fig. 1). 
During the experiments. protection from HgCh autoimmu-
nity was first noticed as less severe skin lesions (Fig. 2) and a 
reduction in weight loss (Table I). Naive BN rats that received 
FK506 with or without syngeneic bone marrow (groups III and 
IV) showed less dermal hair loss and ulceration grossly. and 
less dermal inflammation microscopically. than untreated na-
ive BN rats. However. the BN rats that received allogeneic 
bone marrow and FK506 (group V) were ess~ltially com-
pletely protected (P< 0.(05) (Table I). Microscopically. there 
also was a decrease in renal (Fig. 3) and hepatic inflammation 
and damage in all groups that received pretreatment (groups 
Ill-V) as compared to positive controls (group II). but these 
parameters also were most significant in group V. 
Semi-quantitative grading of immunoglobulin deposits cor-
related excellently with the routine histopathologic findings 
(Table II). Naive BN rats given HgCI2 alone (group II) consis-
tently contained the most intense glomerular capillary loop de-
posits of IgG and IgM. whereas they were less intense in rats 
from groups I I. IV and. particularly. group V (Fig. 3). 
Serological evaluation. Fig. 4 illustrates the significant re-
duction in mean IgG anti-Iaminin levels seen at day 14 in BN 
rats treated with transient FK506. with (group V) or without 
(grOUP III) allogeneic LEW bone marrow. There was also a 
trend towards less autoantibody production in rats treated 
Figure 3. Histological evaluation of haematoxylin and eosin stained 
kidney sections from negative controls (A; group J). positive controls 
(B; group II) and BN rats pretreated with allogeneic bone marrow 
and transient FK506 (C; group VI). 30 d after commencing HgCl1 in-
jections. A mild to moderate diffuse lymphoplasmacytic infiltrate was 
concentrated around the periadventitial sheath of the interlobular ar-
teries and focally extended into the tubular epithelium. This was asso-
ciated with epithelial damage and tubular dilatation in group II ani-
mals (B; high power lower left inset). The renal inflammation and 
damage was significantly less (P < 0.005; see Table II) in Group V 
alone (C). When sections were stained with goat anti-rat IgM anti· 
body. group V animals showed significantly less severe (C. upper 
right inset) linear and granular immune complex deposition than was 
seen in positive controls (B). 
with FK506 and syngeneic bone marrow. but this did not reach 
statistical significance. Protection from IgM anti-Iaminin au-
toantibodies was more easily achieved in all groups and a rise 
was only seen in unprotected (group II) animals (data not 
shown). 
Peripheral blood lymphocyte analysis (Table /1/). As com-
pared to baseline levels on day O. naive BN rats given HgCh 
(group II) showed a significantly increased peripheral blood 
lymphocyte count at day 14 that was largely attributable to a 
significant increase in B cells (OX-33+/CD45RA B cell com-
mon leukocyte antigen). An associated reduction of T helper 
cells (CD5''/CD4+) and in upregulation of MHC class II ex-
pression on T cells (CD5+/MHC class II+) also occurred in 
these animals. 
In contrast to naive BN animals. rats pre-treated with 
FK506 with or without a syngeneic or allogeneic bone marrow 
infusion (groups III-V) showed an increased peripherallym-
phocyte count. a decreased percentage ofT helper cells and an 
increased percentage of MHC class II positive T cells at day O. 
Furthermore. group V animals had significantly higher base-
line B cell levels on day 0 than animals in other groups. These 
findings suggest the presence of low-grade immune activation 
in animals preconditioned with allogeneic bone marrow and 
transient FK506. before the administration of HgCl1. 
After treatment with HgCh. the changes in Band T helper 
leukocyte profiles of preconditioned rats were similar to those 
of naive animals. except for animals protected by allogeneic 
bone marrow and FK506 (group V). In this group and those 
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Figure 4. ELISA for IgG anti-Iaminin autoantibodies in protected 
and unprotected animals after administration of HgCI2• Syngeneic 
BN bone marrow infusion with FKS06 (BNBM + FK; group IV) con-
ferred some protection against elevations of autoantibody titres at 
day 14, however, a significant reduction in peak Ab titre was only 
achieved in animals treated with transient FKS06 alone (FKS06; 
group IV) or allogeneic LEW bone marrow with transient FKS06 
(LEWBM + FK; group V) (*; P < 0.05, Student's t test). No autoan-
tibody increase was seen in the negative control animals treated with 
carrier only (data not shown). Eight samples from each group at each 
time point were examined and assayed in quadruplicate. Results are 
expressed as mean I S.D. for each time point. 
given FK506 alone, the expected reduction of Th cells was not 
seen. More importantly, the significant increase of B cells was 
completely prevented in group Valone, correlating with the 
significantly lower auto-antibody levels, less severe disease 
and prevention of mortality seen in these animals. 
Because of an earlier work describing increased MHC class 
II expression on B cells between days 3 and 15 after treatment 
with HgCI2(31), the protective effect of allogeneic bone mar-
row infusion on this parameter was also assessed by measuring 
the mean channel fluorescence (MCF) intensity of OX-6 ex-
pression on all peripheral blood lymphocytes (as> 95% of 
OX-6+ peripheral blood leukocytes are B cells; data not 
shown). To control for possible slight variations between 
ing intensity on different days, all samples were stained at 
same time for this experiment. On day 0, there was no uuu:r'f',JlIIZ·· 
ence between the MCF, of samples (four animals analyzed 
group) from groups II (no pretreatment), IV (syngeneic 
marrow), and V (allogeneic bone marrow). In contrast. the 
creased MCF. which occurred in group II and IV animals 
day 7 (to 18.8 and 15.9, respectively), was significantly reauce.1ti 
in group V animals (to 13.9; P < 0.01. Student's t test). 
Spontaneous proliferation and autoreactivity assays. 
placed in wells without external stimulation of any kind, 
phocytes from group V animals at day 0 showed 
rates of thymidine incorporation (Fig. 5 A), as compared 
naive BN rats (group II at day 0) and transiently chplf~K 
treated recipients (group III) on day 0, although this did 
reach statistical significance (P = 0.28. Student's t test). The 
same was true fl¥" MLR reactivity at day 0 (Fig. 5 C). Although 
animals from group ~ responded more vigorously to autOllfOo .. ",., .•. gous stimulation, the wide variability between animals made,,, . the results statistically insignificant (P = 0.56). .,' 
Conversely, lymphocytes from group V animals at day K:I~ 
showed significantly less b~line ~roliferation than those fro~ l. 
group II and group IV aDlIDals (FIg. 5 B). and when placed fa~ ;; 
MLR against normal BN stimulators. a significant reduction in 
autoreactivity was seen (Fig. 5 D). 
Discussion 
Several of the treatment regimens used in this study afforded 
some resistance to HgCl2-induced autoimmunity, but the best 
overall serological. histological, and mortality protection was 
seen in animals pretreated with allogeneic bone marrow and 
FK506 (group V). This pretreatment protocol is known to in-
duce hematolymphoid microchimerism for at least 100 d, and 
is associated with donor-specific allogeneic tolerance (15, 23), 
However, the substantial protection afforded by transient FK506 
with or without syngeneic bone marrow (groups III and IV). 
although clearly not as effective as FK506 plus allogeneic bone 
marrow (group V). suggests that transient immunosuppression 
is an important component in the protection protocol. 
Reference to the work of Hess et al. (32) and others on cy-
closporine-induced syngeneic graft-versus-host disease. which 
HgCI2 autoimmunity resembles, provides a possible explana-
Table III. Analysis of Peripheral Blood Lymphocytes of Naive (Group 11), FKS06 Alone (Group Ill), and Syngeneic (Group IV: 
BNBM + FK) and Allogeneic (Group V; LEWBM + FK) Bone Marrow Plus FKS06 Animals Given HgClz from Days 0 to 8 
(Group II) I (Group III) (Group IV) (Group V) 
'1aive (n = 5) FK506 (n = 3) BNBM+FK (n = 7) LEWBM+FK (n = 6) 
Time dayO day 14 day 30 dayO day 14 day 30 JayO day 14 day 30 dayO day 14 day 30 
Lymphocytes 
(X lOo/ml) 7 10· 14· 12* 7 II 12' 10 12 10 \0 IS· 
CDS+ICD4+ 37 2S· 26* 23' 22 22 29 20*' 24 27' 23 23* 
CDS+!CD8+ 3,S 4.9 3.S 7.0' 6.4 4.0 5.S ·tS 4.4 4.S 5.0 4.2 
CDS+!c1ass II MHC 1.4 3.3· 3.0 3,9' 3.S 1.7* 2.7' 3.7* 2.5 3.0* 4.4 3.0 
CD4SRA:B-cell CLA 3<)1' 49* 41 341 44· 53* 3S' SO·, 50* 4S 46 46 
Mean values are presented throughout and significant differences are indicated (Student's t test throughout). Group II animals at day 0 (naive and 
before egCf~ treatment) are used as baseline controls. Percentage of lymphoid-gated events for double stained populations. except OX-33+. • P < 
0.05 vs. dO of same group. 'P < 0.05 vs. group II (naive BN + HgCl2) at same time point. I P < 0,05 vs. group V (allogeneic bone marrow + Hg02) 
at same time point. 'P = 0,06 vs. group V at same point. 
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Figure 5. Spontaneous prolif· 
eration and MLR assays. On 
day 0, before starting HgCI2 
administration. lymphocytes 
from animals given allogeneic 
LEW bone marrow with tran-
sient FK506 at day -} 00 
(LEW + FK; group V) showed 
greater spontaneous prolifera-
tion (A) and an increased abil-
ity to respond to syngeneic 
normal BN lymphocytes in 
MLR (C) than those from nor-
mal BN or FK506 only 
(FK506) animals. although 
this did not reach statistical sig-
nificance (P = 0.28 and P = 
0.58. respectively: Student's r 
test). In contrast. 30 dafter 
starting HgCI2• the spontane-
ous proliferation (B) and au-
tore activity (D) seen in unpro-
tected naive animals (NAIVE: 
group II) and those protected 
with syngeneic BN bone mar-
row and FK506 (BNBM + FK: 
group IV) was significantly re-
duced in animals pretreated 
with allogeneic LEW bone 
marrow and FK506 (P < 0.05. 
Student's r test). (Data shown 
are mean:!:SEM of results with 
at least three animals per 
group). 
tion for the mechanism of action of transient FK506. They periments. resistance to diabetes was conferred when suscepti-
have shown that syngeneic GVHD requires: (a) transient cy- ble rats contained as little as 8.5% of resistant chimeric donor 
closporine, which causes thymic injury. T cell maturational cells in the spleen, and was lost when the chimerism (i.e .. do-
dysregulation and the release of abnormally high numbers of nor cells) was not detectable. 
autoreactive cells into the periphery (33); (b) a thymus, to as- There are several possible explanations for the in vivo pro-
siat in T cell maturation (33); and (e) irradiation or cytoreduc- tection from AI seen in this study. The likelihood of each is 
tive therapy to disable peripheral regulatory networks. indud- considered to be in this order of probability: (a) alloactivation 
ing SO called "internal image" cells. Since FK506 lOJuses thymic of the BN immune system may also stimulate autoreactive T 
injury similar to cydosporine (34-36). it is likely' that FK506 cells and thus mimic the HgCl2-induced autoimmune syndrome. 
also releases autoreactive cells into the periphery. These cells making the animals resistant to further activation or change by 
sbare with those generated during HgCl2-induced autoimmu· HgCI 2: (b) donor LEW T cells contained in the bone marrow 
~tyI a functional specificity for self Ia antigens (32. 37). Thus. inoculum. which are responsive to Ia determinants on BN 
It is not unreasonable to expect that the transient FK506 regi- cells. may mimic AI disease producing BN cells and stimulate 
tnen, like cyclosporin. releases autoreactive cells. that in tum, autoantibody production and thus. regulatory networks: and. 
PI'Oduce an autoaggressive response that stimulates regulatory (e) activation of Thl-type BN T cells by low-grade allostimula-
pathways. Thus. rechallenge of these animals with HgCl" pro- tion may change the cytokine milieu or immunologic microen-
cIuc:es less tissue injury and mortality. vironment of the BN rat. and dampen the Th2-type response 
The hypothesis tested in this paper is that by combining the normally seen after HgClc administration. We cannot confi-
drug effect discussed above with the continued presence of al- dently distinguish between these possibilities at this time. 
~eneic cells. even in small numbers. a prolonged stimulus to However. related studies in our laboratories have shown allo-
IIIponant regulatory pathways might be provided. Indeed. activation of the BN immune system can trigger production of 
Ro.siru et at. have shown the importance of the continued some of the same autoantibodies as those produced during 
P{eaence of a disease resistant population of cells by using HgCl,-induced autoimmunity (Delaney. manuscript in prepa-
'PIenocytes from histocompatible. diabetes-resistant. BBIWF ration). 
dooors in diabetes susceptible BBlWor rats (38). In their ex- Results such as the increased expression of MHC class II 
, 80", M",o'< ",",p"'ow'", wi"D~D /"odi"i"" P'mo<' AI"ooom~in< 223 
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on T cells. increased numbers of B cells and increased mea-
surements of in vitro baseline proliferative and MLR reactivity 
in microchimeric animals protected from the autoimmune dis-
ease suggest that the processes involve cell activation. Such 
data support previous suggestions by Coutinho and others that 
the mechanisms involved in self and allogeneic tolerance are 
active processes (24, 25), and correlate with the active prolifer-
ation known to be associated with microchimerism (39, 40). 
Several other lines of investigation also suggest a direct link 
between al1o- and autoreactivity. and draw attention to strik-
ing similarities between the mechanisms responsible for self 
and allogeneic tolerance. Hess et aI. have shown that autoreac-
. tive CD8 cells emerging during syngeneic graft-versus-host-
disease induced by transient cyclosporine therapy. can prolong 
allograft survival (41). Neonatal allogeneic tolerance achieved 
through hematolymphoid mixed chimerism correlates with 
high levels of T and B lymphocyte reactivity (25), a propensity 
to AI disease (42, 43). and increased production of IL-4. Inter-
estingly, such allogeneic tolerance in neonates can be blocked 
with anti-IL-4 antibodies (44), whereas administration of exog-
enous IL-4 has been shown to restore self-tolerance and pre-
vent diabetes in the NOD mouse by reversing a proliferative 
defect in mature thymocytes (45). 
The results presented in this model show effective preven-
tion of the serious features of HgCl2 autoimmunity, although 
human AI diseases may be more difficult to treat than experi-
mental models. For example. a single blood transfusion can 
prevent diabetes in the BB rat. but repeated allogeneic buffy 
coat transfusions met with little or no success in humans. even 
in the early stages of diabetes (46). However, the transfused 
cells in the above study (46) were HLA-DR identical and no 
significant evidence of lymphoid activation was detected dur-
ing treatment. In clinical solid organ transplantation. where 
intense allostimulation and hematolymphoid microchimerism 
routinely occurs in long term survivors (13), AI disease has a 
relatively low recurrence rate or is noticeably less severe than 
before transplantation (41-52). An important exception to this 
generalization is patients who are HLA identical to the donor. 
in which case recurrent AI disease is common (53). Although 
the potent immunosuppression given to prevent rejection may 
account for these observations, an effect similar to that re-
ported in this manuscript may also be occurring. 
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